Abstract
This mini-review summarizes the development of the derivatives and conjugates of Amphotericin B (AMB) which have not been clinically applied so far but are therapeutically promising. Effects of chemical modifications of AMB upon biological activities of the resulting derivatives are discussed. The examples presented include variation of functional groups in AMB, covalent conjugates with other molecules, poly(ethylene glycols) and polysaccharides. Possibilities of targeted delivery of AMB are discussed.
Keywords: Amphotericin B, antimycotics, systemic mycosis, poly(ethylene glycol), polysaccharides, drug targeting, pHsensitivity, β-glucosidase-sensitivity
Mini-Reviews in Medicinal Chemistry
Title: Amphotericin B: From Derivatives to Covalent Targeted Conjugates
Volume: 9 Issue: 11
Author(s): Milos Sedlak
Affiliation:
Keywords: Amphotericin B, antimycotics, systemic mycosis, poly(ethylene glycol), polysaccharides, drug targeting, pHsensitivity, β-glucosidase-sensitivity
Abstract: This mini-review summarizes the development of the derivatives and conjugates of Amphotericin B (AMB) which have not been clinically applied so far but are therapeutically promising. Effects of chemical modifications of AMB upon biological activities of the resulting derivatives are discussed. The examples presented include variation of functional groups in AMB, covalent conjugates with other molecules, poly(ethylene glycols) and polysaccharides. Possibilities of targeted delivery of AMB are discussed.
Export Options
About this article
Cite this article as:
Sedlak Milos, Amphotericin B: From Derivatives to Covalent Targeted Conjugates, Mini-Reviews in Medicinal Chemistry 2009; 9 (11) . https://dx.doi.org/10.2174/138955709789878178
DOI https://dx.doi.org/10.2174/138955709789878178 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Seeing Genes at Work in the Living Brain with Non-Invasive Molecular Imaging
Current Gene Therapy Hepatitis C Virus Infection and Antiviral Treatment in Marginal Zone Lymphomas
Current Clinical Pharmacology Prospects and Limitations of T Cell Receptor Gene Therapy
Current Gene Therapy New Candidate Genes for Lack of Sensitivity to Therapy in Pediatric Leukemias
Current Cancer Drug Targets Characterization of MHC Ligands for Peptide Based Tumor Vaccination
Current Pharmaceutical Design Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer
Current Medicinal Chemistry Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Expression and Functions of Vasoactive Substances Regulated by Hypoxia-Inducible Factor-1 in Chronic Hypoxemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Anticancer Agents: VTA or VDA
Current Bioactive Compounds Current Advances and Therapeutic Potential of Agents Targeting Dipeptidyl Peptidases-IV, -II, 8/9 and Fibroblast Activation Protein
Current Topics in Medicinal Chemistry The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma
Current Pharmaceutical Design Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion
Current Pharmaceutical Design Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
Current Pharmaceutical Design Looking at Drug Resistance Mechanisms for Microtubule Interacting Drugs: Does TUBB3 Work?
Current Cancer Drug Targets The JAK-STAT Pathway: A Therapeutic Target in Hematological Malignancies
Current Cancer Drug Targets DNA Double Strand Break Repair - Related Synthetic Lethality
Current Medicinal Chemistry Chemoprotection and Selection by Chemotherapy of Multidrug Resistance-associated Protein-1 (MRP1) Transduced Cells
Current Gene Therapy Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets The Interactions of Anti-Cancer Drugs Approved in the Last Decade in the United States with Membrane Transporters
Anti-Cancer Agents in Medicinal Chemistry Small Molecule Antagonists of the Chemokine Receptor CCR5
Current Topics in Medicinal Chemistry